Cancer News

AbbVie and the International Myeloma Foundation Partner to Study Role of a Genetic Mutation in Multiple Myeloma (03/28/2018)

AbbVie a research and development-based global biopharmaceutical company, and the International Myeloma Foundation (IMF) today announced they have entered into a collaboration to conduct a landmark retrospective chart review study to better understand and help manage multiple myeloma (MM), the second most common blood cancer.1 “There are significant knowledge gaps about multiple myeloma, and among …

Continue reading "AbbVie and the International Myeloma Foundation Partner to Study Role of a Genetic Mutation in Multiple Myeloma"

CRISPR Enhances Cancer Immunotherapy (03/14/2018)

Gene editing expands reach of therapeutic T cells, in mice CancerConnect News: Last year, the Food and Drug Administration approved the first cellular immunotherapies to treat cancer. These therapies involve collecting a patient’s own immune cells — called T cells — and supercharging them to home in on and attack specific blood cancers, such as …

Continue reading "CRISPR Enhances Cancer Immunotherapy"

Darzalex-Effective Treatment for Smoldering Multiple Myeloma (03/07/2018)

CancerConnect News: The use of Darzalex (daratumumab) in smoldering myeloma may be effective in delaying the time to disease progression. These results were presented at the 2017 annual meeting of the American Society of Hematology (ASH). Multiple myeloma (MM) is the second most common blood cancer in the United States, with over 30,000 diagnoses expected …

Continue reading "Darzalex-Effective Treatment for Smoldering Multiple Myeloma"

Kyprolis Improves Survival in Recurrent Multiple Myeloma (02/08/2018)

CancerConnect News: The addition of Kyprolis® (carfilzomib) to the standard treatment regimen, Revlimid® (lenalidomide) and dexamethasone, improves survival for patients with multiple myeloma whose disease progressed or recurred following prior therapies. These results were recently presented at the 2017 annual meeting of the American Society of Hematology (ASH). About Multiple Myeloma In the United States …

Continue reading "Kyprolis Improves Survival in Recurrent Multiple Myeloma"

Diagnosed with Multiple Myeloma: 10 Tips on How to Get The Most From Your Doctor (02/07/2018)

1) Choose Your Doctor Carefully Hematologists and oncologists are the primary doctors involved with multiple myeloma and often work in collaboration with stem cell transplant physicians. Pick your primary hematologist/oncologist carefully, rely on people you trust including nurses and other health care professionals who make help with recommendations.  Make sure your doctor is someone you …

Continue reading "Diagnosed with Multiple Myeloma: 10 Tips on How to Get The Most From Your Doctor"

Xgeva Approved for The Treatment of Multiple Myeloma (01/17/2018)

CancerConnect News: The US Food and Drug Administration (FDA) has expanded the approval of Xgeva (denosumab) for the prevention of skeletal-related events in patients with bone metastasis from multiple myeloma. In multiple myeloma, plasma cells infiltrate the bone marrow, spreading into the cavities of all the large bones of the body. In a majority of …

Continue reading "Xgeva Approved for The Treatment of Multiple Myeloma"

Addition of Darzalex™ Improves Outcomes in Newly Diagnosed Multiple Myeloma (12/13/2017)

The addition of Darzalex™ (daratumumab) to the standard treatment combination consisting of Velcade (bortezomib), melphalan, and prednisone (VMP) reduces disease progression or death by 50%, among patients with newly diagnosed multiple myeloma who are not eligible to undergo a stem cell transplant. These results were presented as a late-breaking abstract at the 2017 annual meeting …

Continue reading "Addition of Darzalex™ Improves Outcomes in Newly Diagnosed Multiple Myeloma"

Diagnosed with Multiple Myeloma: 10 Tips on How to Get The Most From Your Doctor (11/20/2017)

1) Choose Your Doctor Carefully Hematologists and oncologists are the primary doctors involved with multiple myeloma and often work in collaboration with stem cell transplant physicians. Pick your primary hematologist/oncologist carefully, rely on people you trust including nurses and other health care professionals who make help with recommendations.  Make sure your doctor is someone you …

Continue reading "Diagnosed with Multiple Myeloma: 10 Tips on How to Get The Most From Your Doctor"

FDA Adds Two Roche Multiple Myeloma Studies Evaluating Checkpoint Inhibitors to List of Partial Clinical Holds Over Safety Concerns (09/25/2017)

Alarmed that an imbalance in deaths among patients taking a combination of Keytruda (pembrolizumab) with Celgene’s Pomalyst and Revlimid could represent a threat in that whole class of checkpoint comboinations, the FDA has added two Tecentriq (atezolizumab) clinical studies to its growing list of clinical trials placed on partial hold over safety concerns while further …

Continue reading "FDA Adds Two Roche Multiple Myeloma Studies Evaluating Checkpoint Inhibitors to List of Partial Clinical Holds Over Safety Concerns"

Four-Year Follow-up with Empliciti Plus Revlimid in Patients with Advanced Multiple Myeloma Shows Long-term Beneift (07/13/2017)

Four-year follow-up data from the Phase 3 ELOQUENT-2 clinical trial in which Empliciti (elotuzumab) plus Revlimid (lenalidomide) continued to demonstrate effectiveness in patients with relapsed/refractory multiple myeloma compared to patients treated with Revlimid alone were recently presented in an oral session today during the 22nd Congress of the European Hematology Association in Madrid, Spain.  Combination …

Continue reading "Four-Year Follow-up with Empliciti Plus Revlimid in Patients with Advanced Multiple Myeloma Shows Long-term Beneift"